文献速递乳腺乳腺X线

对比增强能谱乳腺摄影作为乳腺癌筛查召回患者进一步检查工具风险低且可能具有临床获益

Contrast-enhanced spectral mammography as work-up tool in patients recalled from breast cancer screening has low risks and might hold clinical benefits.
PubMed 文献 · Eur J Radiol · 2017-07-20

研究纳入2012年12月至2015年12月筛查召回后接受对比增强能谱乳腺摄影(CESM)的839例女性,分析辐射剂量与对比剂不良反应,并由经验丰富的乳腺放射科医生回顾所有检查,识别仅由CESM检出的病灶。仅CESM检出的70个病灶中54.3%为恶性,以浸润性导管癌最常见;每次检查中位辐射剂量6.0mGy(0.9-23.4mGy),观察到5例轻微对比剂不良反应。作者结论认为CESM作为筛查召回患者的进一步检查工具对患者风险低,额外检出的肿瘤灶可能具有重要临床意义,需在大型随机对照试验中进一步研究。

要点

  • 仅CESM检出的70个病灶中54.3%为恶性,以浸润性导管癌最常见。
  • 每次CESM检查中位辐射剂量6.0mGy(范围0.9-23.4mGy)。
  • 839例中观察到5例轻微对比剂不良反应,这些病灶活检未观察到并发症。

核心结论

  • CESM作为筛查召回女性的进一步检查工具对患者风险低,额外检出的肿瘤灶可能具有重要临床意义,需在大型随机对照试验中进一步研究。

研究设计与样本

  • 研究纳入2012年12月至2015年12月所有筛查召回后接受CESM的女性,分析辐射暴露与对比剂不良反应例数,并由一名经验丰富的乳腺放射科医生回顾所有检查,识别仅由CESM检出的病灶并对其显著程度评分,收集乳腺密度与最终诊断资料,恶性病例另收集肿瘤分级与受体特征。

关键影像表现/征象

  • 仅CESM检出的70个病灶中54.3%证实为恶性,以浸润性导管癌最常见;其余良性病灶以纤维腺瘤为主;回顾性分析显示多数病灶在低能CESM图像或筛查乳腺X线摄影上为隐匿性或仅表现为「微小征象」。

局限性

  • 额外检出的肿瘤灶可能具有重要临床意义,需在大型随机对照试验中进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Contrast-enhanced spectral mammography (CESM) is a reliable problem solving tool in the work-up of women recalled from breast cancer screening. We evaluated additional findings caused by CESM alone and outweighed them against the disadvantages of this technique.

METHODS: From December 2012 to December 2015, all women recalled from screening who underwent CESM were considered for this study. Radiation exposure and number of adverse contrast reactions were analysed. An experienced breast radiologist reviewed all exams and identified cases with lesions detected by CESM alone and scored their conspicuity. From these cases, data on breast density and final diagnosis were collected. For malignant cases, tumour grade and receptor characteristics were also collected.

RESULTS: During this study, 839 women underwent CESM after a screening recall, in which five minor adverse contrast reactions were observed. Median radiation dose per exam was 6.0mGy (0.9-23.4mGy). Seventy CESM-only lesions were detected in 65 patients. Of these 70 lesions, 54.3% proved to be malignant, most commonly invasive ductal carcinomas. The remaining CESM-only lesions were benign, predominantly fibroadenomas. No complications were observed during biopsy of these lesions. Retrospectively, the majority of the lesions were either occult or a 'minimal sign' on low-energy CESM images or the screening mammogram.

CONCLUSION: Using CESM as a work-up tool for women recalled from screening carries low risk for the patient, while additionally detected tumour foci might hold important clinical implications which need to be further studied in large, randomized controlled trials.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Houben IPL, Van de Voorde P, Jeukens CRLPN, et al. Contrast-enhanced spectral mammography as work-up tool in patients recalled from breast cancer screening has low risks and might hold clinical benefits. Eur J Radiol. 2017. PMID: 28941757. doi:10.1016/j.ejrad.2017.07.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。